The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Does panitumumab have a clinical benefit in cetuximab-refractory KRAS wild-type metastatic colorectal cancer?
Toshiyasu Watanabe
No relevant relationships to disclose
Eiji Shinozaki
No relevant relationships to disclose
Sho Kijima
No relevant relationships to disclose
Yoshihito Ohhara
No relevant relationships to disclose
Yasutoshi Kuboki
No relevant relationships to disclose
Koichi Takagi
No relevant relationships to disclose
Masato Ozaka
No relevant relationships to disclose
Mariko Ogura
No relevant relationships to disclose
Yoshinori Kikuchi
No relevant relationships to disclose
Mitsukuni Suenaga
No relevant relationships to disclose
Keisho Chin
No relevant relationships to disclose
Satoshi Matsusaka
No relevant relationships to disclose
Junichi Koike
No relevant relationships to disclose
Kimihiko Funahashi
No relevant relationships to disclose
Yoshihisa Urita
No relevant relationships to disclose
Nobuyuki Mizunuma
No relevant relationships to disclose
Kiyohiko Hatake
No relevant relationships to disclose
Hironori Kaneko
No relevant relationships to disclose
Motonobu Sugimoto
No relevant relationships to disclose